Scientist gets AHA Research Achievement Award for his leading role in perfecting practice-changing heart disease treatment procedures

November 14, 2016 Categories: Scientific Conferences & Meetings, Heart News

Embargoed until 7 a.m. CT/ 8 a.m. ET, Monday, Nov. 14, 2016

NEW ORLEANS, Nov. 14, 2016 — The American Heart Association presented its Research Achievement Award for 2016 to Robert M. Califf, M.D., “for his visionary clinical research leading to paradigm-changing procedures that have directly and significantly improved, in innumerable ways, the management of patients with cardiovascular disease.”

Califf, now Commissioner of the U.S. Food and Drug Administration, received the award, a citation and $2,500 honorarium, during the opening of the American Heart Association Scientific Sessions 2016 on Sunday, Nov. 13, at the New Orleans Ernest N. Morial Convention Center.  AHA President Steven Houser, Ph.D., of Temple University in Philadelphia, made the presentation.

“Beginning in the mid-1980s, Dr. Califf led a global team of investigators in forming a collaboration to study novel therapeutic approaches for patients with heart disease,” Houser said as he presented the award.  This group carried out 10 multicenter clinical trials that evaluated reperfusion strategies for heart attack. The success of these trials led to a worldwide comparison of the clot-busting drugs streptokinase and tissue plasminogen activator to treat coronary blockages.

Califf was among pioneers creating the Duke University Database for Cardiovascular Disease, which remains the world’s largest and longest-established observational database of cardiovascular patients, Houser said. Using the database, Califf created models to allow clinicians to predict both the presence and severity of coronary artery disease.

“Dr. Califf’s research teams’ and collaborators’ findings have not only made innumerable contributions to our understanding of cardiovascular diseases, including coronary artery disease, heart failure, myocardial infarction and acute coronary syndromes, they have directly and meaningfully impacted the way patients with cardiovascular disease are managed, resulting in practice-changing therapies,” Houser said. He noted that numerous American Heart Association/American College of Cardiology guidelines are based on results of this research.

###

For more news at AHA Scientific Sessions 2016, follow us on Twitter @HeartNews  #AHA16.

For Media Inquiries:

AHA News Media in Dallas: (214) 706-1173

AHA News Media Office, Nov. 12-16, 2016

at the Ernest N. Morial Convention Center: (504) 670-5106   

For Public Inquiries: (800) AHA-USA1 (242-8721)

heart.org and strokeassociation.org

Life is why, science is how . . . we help people live longer, healthier lives.